PR Newswire·Oct 23, 2025, 8:55 AM ET

Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives

ORMP

Oramed Pharmaceuticals Inc. is advancing its oral insulin program independently after terminating its joint venture with Hefei Tianhui Biotech Co. Ltd. due to unmet financial conditions.
The company initiated a 60-patient U.S. trial to validate its oral insulin formulation & refine patient selection criteria for high-responder subgroups, including those with lower BMI & older demographics.
Oramed's diversified investment portfolio generated strong returns, with the Scilex Holdings structured investment returning $95.5 million to date & projected total returns reaching approximately $170 million.
The Alpha Tau Medical investment grew from $37.7 million to a value of $64.8 million as of September 30, 2025, representing a $27.1 million gain & including an investor relations agreement.
BioXcel Therapeutics investment yielded $6.25 million through partial sales as of September 30, 2025, while Oramed maintains 700,000 warrants.
The Pelthos Therapeutics position appreciated by 180%, rising from a $1.5 million investment to a current valuation of $4.2 million as of September 30, 2025.
Oramed reaffirmed its commitment to rewarding shareholders by planning a one-time dividend despite the cancellation of the previous joint venture spin-off.
Total cash & assets increased from $155.7 million in January 2023 to approximately $210 million as of September 30, 2025, despite $17.8 million spent on R&D & share buybacks.
The company is actively pursuing new strategic partnerships & growth initiatives leveraging its network, regulatory expertise, & business development capabilities.